New study aims to perfect antibiotic dosing for sickest kids

NCT ID NCT04961580

Recruiting now Knowledge-focused Sponsor: Children's Hospital of Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the antibiotic ceftazidime avibactam behaves in 30 children with severe infections who are in intensive care, some on life support. Researchers will measure drug levels in the blood to understand the right dose. The goal is to improve treatment for life-threatening sepsis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ceftazidime avibactam sodium (a strong antibiotic)
What this could lead to: If successful, this could help doctors give the right dose of this antibiotic to critically ill children, potentially improving survival from severe sepsis.
What could go wrong: This is a very small, early-stage study (30 children) that only measures drug levels, not cure rates. Results may not apply to all children or lead to a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTIBIOTIC REACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

drug allergy infectious disease infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTIBIOTIC REACTION SEPSIS

Contacts and locations

Locations

Children's hosptial of fudan university
RECRUITING

Shanghai, Shanghai Municipality, 201102, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.